Artikel
The effects of low bone mineral density on pain, quality of life and fatigue in the patients with epilepsy
Suche in Medline nach
Autoren
Veröffentlicht: | 16. April 2019 |
---|
Gliederung
Text
Background: Low bone mineral density (BMD) may occur in epilepsy patients due to antiepileptic use [1].
Aim: To investigate the effects of low BMD seen in epileptic patients who use antiepileptics on pain, quality of life (QoL) and fatigue.
Method: Epileptic patients with bone mineral density (BMD) below -1.5 or with a previous fracture history were recruited in the study group. The remaining patients were included in the control group. Demographic and clinical features (duration of epilepsy and antiepileptic use, types of antiepileptics, previous fracture history, BMD scores, vitamin D levels, FRAX assessments) were recorded. Back pain measured with visual analogue scale (VAS) and brief pain inventory (BPI), QoL assessed with Qualeffo-41, fatigue assessed with fatigue severity scale (FSS) were noted as functional parameters.
Results/findings: Study group included 21 patients (11 female, 10 male) and control group included 23 patients (13 female, 11 male). Mean age and disease duration of all participants were 40.8 (±11.6) years and 20.7 (±13) years, respectively. Nine patients (20.5%) had a previous fracture history. The median scores of VAS, Qualeffo-41, FSS, pain severity and pain interference of BPI were significantly found higher in study group when compared to control. There was significant correlation between lumbar spinal BMD and VAS (rho= -0.51, p<0.0005), BPI-pain severity (rho=-0.51, p<0.0005), BPI-pain interference (rho=-0.45, p=0.002) and Qualeffo-41 (rho=-0.36, p=0.01), and FSS (rho=-0.32, p=0.03).
Discussion and conclusions: Epileptic patients suffering from low BMD showed increased pain, fatigue and impaired QoL. It has been suggested that BMD measurement should be recommended for the evaluation and management of epileptic patients in follow-up period.
References
- 1.
- Lazzari AA, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy—antiepileptic drug and osteoporosis prevention trial. Epilepsia. 2013;54(11):1997-2004.